Out of the 191 plant species (genera) included in the protection lists maintained by the Ministry of Agriculture and Rural Affairs, a mere 30 are considered medicinal species (genera). Despite the broader scope of the Protection List of New Plant Varieties of the People's Republic of China (Forest and Grass), a mere 29 of the 293 listed species (genera) qualify as Chinese medicinal plants. A rarity of PVP applications and authorizations for Chinese medicinal plants, alongside an unsatisfactory variety composition, stands out. Inobrodib Thus far, 29 species (or genera) of DUS test guidelines for Chinese medicinal plants have been formulated. The development of novel Chinese medicinal plant varieties faces challenges, including the scarcity of new strains and the inadequate exploitation of the nation's Chinese medicinal plant resources. The current state of breeding new Chinese medicinal plant varieties, the advancements in DUS testing guidelines within China, and the use of biotechnology in this field, along with the difficulties in DUS testing, were explored in this paper. Protecting and leveraging the valuable germplasm resources of Chinese medicinal plants is addressed in this paper, with an emphasis on the further application of DUS.
The traditional Chinese medicinal ingredient Poria (Fu Ling) is known for its extensive history and wide range of types. The royal medical records from the Qing Dynasty meticulously list Fu Ling, including its variations such as Bai Fu Ling (white Poria), Chi Fu Ling (red Poria), and Zhu Fu Ling (cinnabar-processed Poria). Preserved within the Palace Museum are six distinct specimen types: Fu Ling Ge (dried Poria), Bai Fu Ling, Chi Fu Ling, Zhu Fu Ling, Bai Fu Shen (white Poria cum Radix Pini), and Fu Shen Mu (Poria cum Radix Pini). Following trait identification and textual analysis, we discovered that Fu Ling Ge represented an entire sclerotium, subsequently transformed into Fu Ling Pi (Poriae Cutis), Bai Fu Ling, and other medicinal components within the Palace. The Qing Dynasty palace's Fu Ling supply was largely dependent on tribute from Yunnan-Guizhou officials. Throughout the Qing Dynasty, the tribute system remained relatively stable, experiencing a transformation only during its later years. The cultural relics of Fu Ling found within the Qing Dynasty Palace concur with the data found in royal medical records and herbal medicine books, thus offering a detailed historical picture of Fu Ling during the Qing Dynasty and a blueprint for recreating its processing methods from that era.
Recent advancements in traditional Chinese medicine (TCM) applications for psoriasis, spanning the last ten years, are examined here, encompassing a review of research areas, current trends, and scholarly recommendations. A bibliometric analysis, using the available literature on TCM intervention for psoriasis, statistically examined trends, content, and source publications. CiteSpace's knowledge map analysis method was employed to examine the research collaboration and keyword co-occurrence patterns within this field. The count of Chinese papers amounted to 2,993, and English papers to 285. With respect to publication trends, English paper output demonstrated a low annual rate coupled with a marked upward trend, in contrast to Chinese paper output which fluctuated with a general lack of significant increase. From the content analysis of Chinese publications, the discipline of Traditional Chinese Medicine (TCM) topped the list with 2,415 entries. Amongst publications in English papers, pharmacology and pharmaceutical science held the top position, with eighty-seven articles. A study of literary sources revealed that the China Journal of Traditional Chinese Medicine and Pharmacy held the top position for Chinese publications, while Evidence Based Complementary and Alternative Medicine topped the English-language list. In China, Beijing University of Chinese Medicine's research culminated in a record-breaking 99 dissertations. LI Bin, of Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine, and LU Chuan-jian, from Guangdong Hospital of Traditional Chinese Medicine, were the authors with the most publications in both Chinese and English. Medicines procurement A CiteSpace analysis of research collaboration networks unveiled four robust, consistent core teams, although collaboration among different teams exhibited low intensity. CiteSpace's analysis of co-occurring keywords reveals that psoriasis, blood-heat syndrome, blood-stasis syndrome, fire needle, blood-dryness type, imiquimod, TCM bath, etiology and pathogenesis, cytokines, and cupping therapy are currently prominent keywords in this field. Chinese scholars have been diligently researching and actively exploring the use of Traditional Chinese Medicine in psoriasis treatment over the past decade. A promising trend of development is apparent, accompanied by a sustained expansion of the research's range and in-depth analysis. A call is made for research pertinent to the topic to be free from the limitations of academic disciplines, thereby promoting interdisciplinary collaboration.
In this study, network meta-analysis was applied to compare the effectiveness of Qi-benefiting and blood-activating Chinese patent remedies for the treatment of ischemic stroke. Across multiple databases, including CNKI, Wanfang, VIP, SinoMed, PubMed, EMbase, and the Cochrane Library, a thorough search for randomized controlled trials (RCTs) on the treatment of ischemic stroke with 11 Qi-benefiting and blood-activating Chinese patent medicines was carried out from their respective inception dates to October 2022. A risk of bias plot was produced by RevMan 5.3, and subsequent network meta-analysis and efficacy ranking were performed using Stata 17. The analysis incorporated ninety-two randomized controlled trials with a total of 10,608 patients. The network meta-analysis utilizing SUCRA as a measure of clinical total effective rate, compared Qilong Capsules with conventional Western medicine to other treatments. This comparison showed Qilong Capsules at the top, followed by Zhishe Tongluo Capsules and Longshengzhi Capsules and continuing the ranking down through the remaining listed treatments, ending with an equivalence between Tongxinluo Capsules and Naomaitai Capsules compared to conventional Western medicine. An analysis of treatment efficacy on National Institutes of Health Stroke Scale (NIHSS) scores was conducted. The use of Longshengzhi Capsules combined with conventional Western medicine proved most effective in improving NIHSS scores. This approach exhibited a better outcome than that of Naomaitai Capsules combined with conventional Western medicine. Furthermore, the combination of Naoxintong Capsules and conventional Western medicine exhibited a greater improvement compared to the Dengzhan Shengmai Capsules plus conventional Western medicine treatment. The Xiaoshuan Changrong Capsules with conventional Western medicine showed better performance than the Naoluotong Capsules combined with conventional Western medicine. The Tongxinluo Capsules and conventional Western medicine combination demonstrated a favorable effect compared to the Naoan Capsules combined with conventional Western medicine, which ultimately exhibited improved results than the combination of Qilong Capsules and conventional Western medicine. Multi-functional biomaterials The combined therapy of Qi-benefiting and blood-activating Chinese patent medicines with conventional Western medicine demonstrated a lower rate of adverse effects/events compared to the control group's outcomes related to safety. Preference was given to the combination therapy of Qilong Capsules and conventional Western medicine, as well as Zhishe Tongluo Capsules and conventional Western medicine, in order to improve the overall clinical efficacy. In the context of bettering NIHSS scores, Longshengzhi Capsules together with conventional Western medicine and Naomaitai Capsules in conjunction with conventional Western medicine were initially considered the best options. With insufficient direct comparisons of drugs, the RCTs displayed lower-than-desirable overall quality, consequently requiring more studies to confirm the strength of the supporting evidence.
Seeking to provide evidence for clinical practice, this study conducts a systematic review of Gusongbao preparation's efficacy and safety in the management of primary osteoporosis (POP). From inception to May 31, 2022, the relevant research papers were retrieved from four Chinese and four English academic journal databases. Following a screening process based on inclusion and exclusion criteria, the randomized controlled trial (RCT) evaluating Gusongbao preparation for POP treatment was incorporated. Risk assessment tools were used to evaluate the quality of articles, and RevMan 53 conducted a meta-analysis on the extracted data. Out of the 657 articles retrieved, this study utilized 15, which incorporated 16 randomized controlled trials. A total of 3,292 patients participated in this study, categorized into 1,071 in the observation group and 2,221 in the control group respectively. Gusongbao preparation, combined with conventional treatment, outperformed conventional treatment alone in boosting lumbar spine (L2-L4) bone mineral density (MD=0.003, 95%CI[0.002, 0.004], P<0.00001), femoral neck bone mineral density, decreasing low back pain (MD=-1.69, 95%CI[-2.46,-0.92], P<0.00001), and enhancing clinical efficacy (RR=1.36, 95%CI[1.21, 1.53], P<0.00001). The clinical efficacy of Gusongbao preparation exhibited a similarity to that of analogous Chinese patent medicines, with a relative risk of 0.95 (95% confidence interval 0.86-1.04), and statistical significance (p=0.023). Gusongbao's performance in reducing traditional Chinese medicine syndrome scores fell short of similar Chinese patent medications (MD = 108, 95%CI [044, 171], P = 0.00009), and its impact on Chinese medicine syndrome efficacy was also comparatively less effective (RR = 0.89, 95%CI [0.83, 0.95], P = 0.00004). Gusongbao's incidence of adverse effects, whether administered alone or with conventional therapies, demonstrated a similarity to those of comparable Chinese patent medicines (RR = 0.98, 95% CI [0.57, 1.69], P = 0.94) or conventional treatments (RR = 0.73, 95% CI [0.38, 1.42], P = 0.35), with gastrointestinal discomfort being the primary manifestation.